Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J; Spanish Oncology Genitourinary Group. Bellmunt J, et al. Among authors: taron m. Ann Oncol. 2007 Mar;18(3):522-8. doi: 10.1093/annonc/mdl435. Epub 2007 Jan 17. Ann Oncol. 2007. PMID: 17229776 Free article.
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R; Spanish Lung Cancer Group. de las Peñas R, et al. Among authors: taron m. Ann Oncol. 2006 Apr;17(4):668-75. doi: 10.1093/annonc/mdj135. Epub 2006 Jan 11. Ann Oncol. 2006. PMID: 16407418 Free article.
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P. Isla D, et al. Among authors: taron m. Ann Oncol. 2004 Aug;15(8):1194-203. doi: 10.1093/annonc/mdh319. Ann Oncol. 2004. PMID: 15277258 Free article. Clinical Trial.
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba JL, Vieitez JM, Maeztu I, Sanchez JJ, Queralt C, Mayo C, Mendez P, Moran T, Taron M. Cortes-Funes H, et al. Among authors: taron m. Ann Oncol. 2005 Jul;16(7):1081-6. doi: 10.1093/annonc/mdi221. Epub 2005 Apr 25. Ann Oncol. 2005. PMID: 15851406 Free article.
Usefulness of predictive tests for cancer treatment.
Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M. Rosell R, et al. Among authors: taron m. Bull Cancer. 2006 Aug;93(8):E101-8. Bull Cancer. 2006. PMID: 16935774 Free article. Review.
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, Sève P. Reiman T, et al. Among authors: taron m. Ann Oncol. 2012 Jan;23(1):86-93. doi: 10.1093/annonc/mdr033. Epub 2011 Apr 6. Ann Oncol. 2012. PMID: 21471564 Free PMC article.
Drug resistance in non-small cell lung cancer.
Monzo M, Rosell R, Taron M. Monzo M, et al. Among authors: taron m. Lung Cancer. 2001 Dec;34 Suppl 2:S91-4. doi: 10.1016/s0169-5002(01)00355-5. Lung Cancer. 2001. PMID: 11720748
156 results